Page 23 - 09 EMA

ndication

diseasemodifying antirheumatic drugs (DMARDs), including
methotrexate, has been inadequate;
 adult patients with severe, active and progressive disease not
previously treated with methotrexate or other DMARDs.
n these patient populations, a reduction in the rate of the progression of
oint damage, as measured by Xray, has been demonstrated.
Adult Crohns disease
Remsimais indicated for:
 treatment of moderately to severely active Crohns disease, in
adult patients who have not responded despite a full and
adequate course of therapy with a corticosteroid and / or an
immunosuppressant or who are intolerant to or have medical
contraindications for such therapies;
 treatment of fistulising, active Crohns disease, in adult patients
who have not responded despite a full and adequate course of
therapy with conventional treatment (including antibiotics,
drainage and immunosuppressive therapy).
Paediatric Crohns disease
Remsimais indicated for treatment of severe, active Crohns disease in
hildren and adolescents agedsix to 17years, who have not responded to
onventional therapy including a corticosteroid, an immunomodulator
and primary nutrition therapy; or who are intolerant to or have
ontraindications for such therapies. Infliximab has been studied only in
ombination with conventional immunosuppressive therapy.
Ulcerative colitis
Remsimais indicated for treatment of moderately to severely active
ulcerative colitis in adult patients who have had an inadequate response
o conventional therapy including corticosteroids and 6mercaptopurine
6MP) or azathioprine (AZA), or who are intolerant to or have medical
ontraindications for such therapies.
Paediatric ulcerative colitis
Remsimais indicated for treatment of severely active ulcerative colitis in

- 12 -